Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly Change in Account Payables came in at $429251.0 in Q1 2026, down 36.95% year-on-year from $680824.0 in Q1 2025, and down 20.14% on a QoQ basis from $537526.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Change in Account Payables data on file, last reported at $429251.0 in Q1 2026.
- On a quarterly basis, Change in Account Payables fell 36.95% year-over-year to $429251.0 in Q1 2026; TTM through Mar 2026 was -$104746.0, a 122.13% decrease from a year earlier, with the FY2025 full-year figure at $146827.0, down 45.98% from the prior year.
- Change in Account Payables for Q1 2026 stood at $429251.0, down from $537526.0 in the prior quarter.
- Over the last five years, Change in Account Payables for IKT reached as high as $911832.0 in Q2 2025 and fell as low as -$2.0 million in Q3 2025.
- Historically, Change in Account Payables has averaged $23814.6 across 5 years, with a median of $54248.0 in 2022.
- On a YoY basis, Change in Account Payables climbed as much as 2415.21% in 2024 and fell as far as 1104.36% in 2024.
- Year by year, Change in Account Payables stood at $369950.0 in 2022, then plunged by 123.73% to -$87794.0 in 2023, then slumped by 1104.36% to -$1.1 million in 2024, then surged by 150.84% to $537526.0 in 2025, then retreated by 20.14% to $429251.0 in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $429251.0 in Q1 2026, $537526.0 in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 16.86 Mn |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | 429,251.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 429,251.00 |
| Mar 31, 2026 | 429,251.00 |
| Dec 31, 2025 | 537,526.00 |
| Dec 31, 2025 | 537,526.00 |
| Sep 30, 2025 | -1.98 Mn |
| Sep 30, 2025 | -1.98 Mn |
| Jun 30, 2025 | 911,832.00 |
| Jun 30, 2025 | 911,832.00 |
| Mar 31, 2025 | 680,824.00 |
| Mar 31, 2025 | 680,824.00 |
| Dec 31, 2024 | -1.06 Mn |
| Dec 31, 2024 | -1.06 Mn |
| Sep 30, 2024 | 453,434.00 |
| Sep 30, 2024 | 453,434.00 |
| Jun 30, 2024 | 396,434.00 |
| Jun 30, 2024 | 396,434.00 |
| Mar 31, 2024 | 479,267.00 |
| Mar 31, 2024 | 479,267.00 |
| Dec 31, 2023 | -87,794.00 |
| Dec 31, 2023 | -87,794.00 |